The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.
Quantification of human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies is considered to be an important parameter in evaluating candidate vaccines. Most previous studies have failed to detect vaccine-induced antibodies against primary isolates, which are more resistant to antibody mediated neutralization compared with laboratory isolates, in neutralization assays. In this study, sera from a prime boost vaccination strategy of a phase I clinical trial were tested against six clade B primary HIV-1 isolates and single isolates of clades C and F. These sera produced statistically significant neutralization against primary isolates MN, SF13, SF162 and Han 2 but not the most resistant subtype B isolates (92US077 and 93US143) nor the subtype C and F isolates. These data suggest that the sera from vaccinated volunteers have subtype-specific neutralizing antibodies against primary HIV-1 isolates. We recommend using assays with extended incubation phases to monitor current HIV vaccine efficacy trials.
Donners
Helen
H
Department of Microbiology, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium.
Vermoesen
Tine
T
Willems
Betty
B
Davis
David
D
van der Groen
Guido
G
D016915:AIDS Vaccines / Q000276:immunology*; D000918:Antibody Specificity; D015704:CD4 Antigens / Q000276:immunology; D002460:Cell Line; D024882:Drug Resistance, Viral; D005456:Fluorescent Dyes; D015483:HIV Antibodies / Q000032:analysis / Q000096:biosynthesis*; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests
D016915:AIDS Vaccines; D015704:CD4 Antigens; D005456:Fluorescent Dyes; D015483:HIV Antibodies